2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W011963
    Melevodopa hydrochloride 1421-65-4 ≥98.0%
    Melevodopa hydrochloride is an effervescent Levodopa (HY-N0304) prodrug. Levodopa is an orally active metabolic precursor of neurotransmitters dopamine and has anti-allodynic effects and the potential for Parkinson's disease
    Melevodopa hydrochloride
  • HY-W016388
    9-Fluorenol 1689-64-1 ≥98.0%
    9-Fluorenol (9-Hydroxyfluorene; compound 3) is a dopamine (DAT) inhibitor with IC50 value of 9 µM. 9-Fluorenol is a major metabolite of compound developed as a wake promoting agent. 9-Fluorenol shows wake promotion activity in vivo.
    9-Fluorenol
  • HY-W105505
    SAMe-1,4-Butanedisulfonate 101020-79-5 98.03%
    SAMe-1,4-Butanedisulfonate, a natural compound, is a methyl donor in the central nervous system. SAMe-1,4-Butanedisulfonate has antidepressant activity. SAMe-1,4-Butanedisulfonate can be used for research of CNS disorders.
    SAMe-1,4-Butanedisulfonate
  • HY-W130025
    p-Xylene bis(pyridinium bromide) 14208-10-7 99.60%
    p-Xylene bis(pyridinium bromide) (compound 21), a cationic charged quencher, is a week bisquaternary AChE and BChE inhibitor with IC50s of 1540 μM and 529 μM, respectively.
    p-Xylene bis(pyridinium bromide)
  • HY-W324391
    Coumarin 106 41175-45-5 99.76%
    Coumarin 106 (Coumarin 478) is a dipolar laser dye. Coumarin 106 is an inhibitor of AChE and BChE. Coumarin 106 displays mixed-type AChE inhibition with a pIC50=4.97 and Ki=2.36 μM. Coumarin 106 inhibits BChE with slightly lower potency (pIC50=4.56).
    Coumarin 106
  • HY-N0830S10
    Palmitic acid-13C2 86683-25-2 99.54%
    Palmitic acid-13C2 is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-13C2
  • HY-12882
    Ifenprodil 23210-56-2 99.94%
    Ifenprodil (NP-120), a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM). Ifenprodil is an α1 adrenergic receptor antagonist. Ifenprodil inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil has reliable inhibitory effects against A/H1N1 strains (EC50 of 6.6 µM). Ifenprodil has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease.
    Ifenprodil
  • HY-14256
    BMS-191095 166095-21-2 98.01%
    BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels.
    BMS-191095
  • HY-19489S
    (±)-Levomepromazine-d6 1189805-51-3 ≥98.0%
    (±)-Levomepromazine-d6 is the deuterium labeled Methotrimeprazine, which is a D3 dopamine and Histamine H1 receptor antagonist.
    (±)-Levomepromazine-d6
  • HY-10559
    Nelotanserin 839713-36-9 99.52%
    Nelotanserin is a potent 5-HT2A inverse agonist, a moderately potent 5-HT2C partial inverse agonist and a weak 5-HT2B inverse agonist, with IC50s of 1.7, 79, 791 nM in IP accumulation assays, respectively.
    Nelotanserin
  • HY-10934
    Mibampator 375345-95-2 99.86%
    Mibampator (LY451395) is a potent and highly selective potentiator of the AMPA receptors.
    Mibampator
  • HY-14503
    MDR-1339 1018946-38-7 98%
    MDR-1339 (DWK-1339) is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease.
    MDR-1339
  • HY-112437
    PF-06737007 1863905-38-7 99.70%
    PF-06737007 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 7.7 nM, 15 nM and 3.9 nM for TrkA, TrkB and TrkC, respectively. Anti-hyperalgesic effect.
    PF-06737007
  • HY-112700
    SHIP2-IN-1 2252247-80-4 99.72%
    SHIP2-IN-1 is a potent SHIP2 inhibitor, inhibits SHIP2 activity, with an IC50 of 2 μM. SHIP2-IN-1 blocks GSK3β activation by phosphorylation at the Ser9 residue. SHIP2-IN-1 is used in the research of Alzheimer’s disease.
    SHIP2-IN-1
  • HY-136788
    ALK4290 1251528-23-0 99.79%
    ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism.
    ALK4290
  • HY-14541S
    Olanzapine-d3 786686-79-1 99.09%
    Olanzapine-d3 is the deuterium labeled Olanzapine. Olanzapine is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptors (Ki=19 nM). Olanzapine is an atypical antipsychotic.
    Olanzapine-d3
  • HY-156679
    VK-0214 852949-30-5 99.87%
    VK-0214 is an agonist of the thyroid β receptor (TRβ). By activating the expression of ABCD2, it can reduce the accumulation of very long-chain fatty acids (VLCFAs) and further alleviate glioblastoma multiforme. VK-0214 has the effect of regulating fatty acid metabolism and can be used in the research of X-linked adrenoleukodystrophy (X-ALD).
    VK-0214
  • HY-17631A
    Edonerpic maleate 519187-97-4 99.79%
    Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).
    Edonerpic maleate
  • HY-106443B
    Arimoclomol citrate 368860-21-3 99.76%
    Arimoclomol citrate (BRX-220 citrate) is an orally active co-inducer of heat shock proteins (HSP). Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system. Arimoclomol citrate can be used for the study of Niemann–Pick disease type C.
    Arimoclomol citrate
  • HY-B0158S6
    Cytidine-15N3 99.3%
    Cytidine-15N3 is the 15N labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
    Cytidine-15N3
Cat. No. Product Name / Synonyms Application Reactivity